9999999997-18-005827.txt : 20180522
9999999997-18-005827.hdr.sgml : 20180522
20180522155448
ACCESSION NUMBER: 9999999997-18-005827
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20180522
DATE AS OF CHANGE: 20180522
ACTION DATE: 20180522
RECEIVED DATE: 20180522
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 18852378
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S
M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR
M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T
M:" V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G (.=@94P C$+ P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@
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M3.=>UM4F47I%EO9 ;R@GZ=M!G7J2
MZN#\-G?2;%2I(8H9N9.';RK;[37BI.1>.=>(LY#,\LVUKV(.O<[ML^+?,BJT\LQ7@7=\ZUDR![L.M08\T.S9!YR.;S/Z3K
MSP<^RW;:\?"? , Y]*'- T*96YD!3EG%@D&T'C$. ?_B5!I $8SJ.
M('L=!/""_UFA'V\# E[V]X"-P6>4Q9#-W$SVJQOX(4W3\UN?!@%+]78W>!O\
M09Y6RVSN^1%-R0S6GA_3A&0>9622V=FYFP3OS^S;P!_1)(FO?08CYU,/M,_U
M?/KTN,R6'JZ.T %,5C/ 0T(Z(K]/OTY6=\Z Z]_7*]7CZLK/N$INS"N_;)
MM'/?C3#I^_P(G ^!!YBYR9+%]'+3+4 Q34QK18F*,9I%&$U^MW<[8ZYW;V[ @0DU6:2A/:P,?:K
M-T92RJX3)>0UY/M])8O,#L>&7OCR:Z%K((=%H]P[%OB_P1:+6_94MIX_IA:&IM7)K#BIQP*,\(3/
M+9DL9&8O'HT\E]DJT")')OH7-$6Y(;([@ 1V?4T][MZ'3N :N
MV^4=/F1KT,7NB.CBPV2=.'!_'/)*VI=2%SDDHH6\=3B80ZY0B$XE3\\E=]6N
MH&A>7X4J]+!1B&B=U\; \QNE^Z,E)">Y+6"B._8IB?B$<&Q].X9J,XF>
MO:$Y<";_D:UVB8>=P-29VV^004F72.ZIRI
M*Q6JJ$+ME.=R) :X7FA.+,R*Y7097%3H]G;:-E75O.FV(*RTX$U6E4EO(VP/
MY=C=1K=7:&(#4J(2AO:(A3[2X@$8G#$[^>IA 8G0Q,2H]D+)IH1V+PJYE:+\
M_)_$AN='J4, H.\!X)GVJ34+'DLCTR%4?:
M%AV9K$P+/\> GYLF;B)\OQ,$[+JE+USZ4Q23R5^VFH1#W0EN6&EK-,:?$>^H
MB"4VF(N[KR?E$*%6[2&O#0WMSPKCY?(B66ZR4W-\FAVS5*=L?/?4;O5. T
MZ,$Q^./G"R(YXD1I0,=87?V%ETRMIP.\:]!&)1"P]C=M1]@SJ+5-'6*RT!;#
M:=FO/SFJ](#CH+0[6FVGN/3R\K*B->2(3N3 SUH42G2Y.II[\".&_2^#>3;X
M5X ! )_&N<,-"F5N9'-T,E,P4#!7,+10L+'1]RO-+8X&<0T4@F+M[( BP?HN=G8
M 08 C84(-PT*96YDFMC.60B
M/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T
M:STB061O8F4@6$U0($-O"UN&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT&UP.D-R96%T;W)4;V]L/@H@(" @
M(" @(" \>&UP.DUO9&EF>41A=&4^,C Q."TP-2TR,E0Q-3HU-#HP.2TP-#HP
M,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#$X+3 U+3(R5#$U.C4T.C Y+3 T.C P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/&1C.F9O"UD969A=6QT(CY-:6-R
M;W-O9G0@5V]R9" M($EN8WET92!#;W)P+B S-C,X-RYD;V-X/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO&UP34TZ26YS=&%N8V5)1#YU=6ED.C%F93%B-#4Q+69B8F$M-&$X,"UA
M,C-A+6(Q9# S865A,6(V8SPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#POJ'5!:DZ@?,S!BL(P$(#A5YF;R:%I&HU6D8+8!07%@K*]]-)-(AL('9F.Z+[]
M]K#GO?_?OP8-VVV^>_(WDCAZYR#JC=%%J:TQA;4+O<[T
M8J;U[*^:6'-U%!]LE4\)/@.-DP2KC#(R/Z/_?](0^J<+)':.\*MGJ./(,:5
M4)1*0R?:.'A\C9V4^2UR"N(Z:%@OIR7*^71O655
M_0HP )/20ML-"F5N9'-TF4@,3 O5'EP92]84F5F+U=;,2 R
M(#%=/CYS=')E86T-"FC>8F( B9&KN4,3 R,;4""=Q6(U0LB1($2SSJ + 8&
M1B#!]!](,#( !!@ >D4%&PT*96YD